Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 339

1.

[CiTIQUE's participative research].

Cosson JF, Brun-Jacob A, Marchand J, Boniface P, Ortmans C, Salvat G, Armand JM.

Sante Publique. 2019 May 13;S1(HS):89-90. doi: 10.3917/spub.190.0089. French. No abstract available.

PMID:
31210495
2.

A modelling approach for the nonlinear dynamics of assembled structures undergoing fretting wear.

Armand J, Pesaresi L, Salles L, Wong C, Schwingshackl CW.

Proc Math Phys Eng Sci. 2019 Mar;475(2223):20180731. doi: 10.1098/rspa.2018.0731. Epub 2019 Mar 20.

PMID:
31007551
3.

Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity.

Chamseddine AN, Ducreux M, Armand JP, Paoletti X, Satar T, Paci A, Mir O.

Pharmacol Ther. 2019 Jul;199:1-15. doi: 10.1016/j.pharmthera.2019.03.002. Epub 2019 Mar 1. Review.

PMID:
30831128
4.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Soria JC, Cortes J, Massard C, Armand JP, Andreis D, Ropert S, Lopez E, Catteau A, James J, Marier JF, Beliveau M, Martell RE, Baselga J.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy532. [Epub ahead of print] No abstract available.

PMID:
30624604
5.

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

Watson S, Menis J, Baldini C, Martin-Romano P, Michot JM, Hollebecque A, Armand JP, Massard C, Soria JC, Postel-Vinay S, Paoletti X.

Br J Cancer. 2018 Oct;119(8):937-939. doi: 10.1038/s41416-018-0245-0. Epub 2018 Oct 17.

6.

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.

Bernard-Tessier A, Baldini C, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2018 Sep;101:160-164. doi: 10.1016/j.ejca.2018.06.005. Epub 2018 Jul 30.

PMID:
30071444
7.

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience.

Besle S, Schultz E, Hollebecque A, Varga A, Baldini C, Martin P, Postel-Vinay S, Bahleda R, Gazzah A, Michot JM, Marabelle A, Angevin E, Armand JP, Ribrag V, Soria JC, Massard C.

Eur J Cancer. 2018 Jul;98:17-22. doi: 10.1016/j.ejca.2018.04.019. Epub 2018 May 30.

PMID:
29859337
8.

Therapeutics discovery: From bench to first in-human trials.

Al-Hujaily EM, Khatlani T, Alehaideb Z, Ali R, Almuzaini B, Alrfaei BM, Iqbal J, Islam I, Malik S, Marwani BA, Massadeh S, Nehdi A, Alsomaie B, Debasi B, Bushnak I, Noibi S, Hussain S, Wajid WA, Armand JP, Gul S, Oyarzabal J, Rais R, Bountra C, Alaskar A, Knawy BA, Boudjelal M.

Biomed Rep. 2018 Mar;8(3):275-282. doi: 10.3892/br.2018.1052. Epub 2018 Jan 31.

9.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.

10.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.

Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.

PMID:
29413684
11.

Colchicine is an active treatment for everolimus-induced oral ulcers.

Ropert S, Coriat R, Verret B, Perret A, Lucibello F, Chamseddine AN, Armand JP, Paci A, Mir O.

Eur J Cancer. 2017 Dec;87:209-211. doi: 10.1016/j.ejca.2017.09.020. Epub 2017 Oct 13. No abstract available.

PMID:
29037756
12.

The European Cancer Patient's Bill of Rights, update and implementation 2016.

Højgaard L, Löwenberg B, Selby P, Lawler M, Banks I, Law K, Albreht T, Armand JP, Barbacid M, Barzach M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore-Booth J, Henning G, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier-Bernard G, Sullivan R, Tabernero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P.

ESMO Open. 2017 Jan 6;1(6):e000127. doi: 10.1136/esmoopen-2016-000127. eCollection 2016. Review.

13.

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S, Varga A, Bahleda R, Menis J, Gazzah A, Michot JM, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2017 Oct;84:212-218. doi: 10.1016/j.ejca.2017.07.027. Epub 2017 Aug 18.

PMID:
28826074
14.

Sequential Regioselective C-H Functionalization of Thiophenes.

Daniels MH, Armand JR, Tan KL.

Org Lett. 2016 Jul 15;18(14):3310-3. doi: 10.1021/acs.orglett.6b01205. Epub 2016 Jul 7.

PMID:
27388746
15.

[What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].

Schernberg A, Marabelle A, Massard C, Armand JP, Dumont S, Deutsch E, Dhermain F.

Bull Cancer. 2016 May;103(5):484-98. doi: 10.1016/j.bulcan.2016.02.014. Epub 2016 Mar 28. Review. French.

PMID:
27032303
16.

Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O.

Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5. Review.

PMID:
26765102
17.

Preface.

Armand JP, Ju L.

Chin Clin Oncol. 2015 Dec;4(4):E2. doi: 10.3978/j.issn.2304-3865.2015.12.09. No abstract available.

18.

Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.

Aspeslagh S, Marabelle A, Soria JC, Armand JP.

Chin Clin Oncol. 2015 Dec;4(4):48. doi: 10.3978/j.issn.2304-3865.2015.12.06. Review.

19.

Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works?

Mir O, Dumont S, Armand JP.

Ann Oncol. 2015 Jul;26(7):1277-8. doi: 10.1093/annonc/mdv246. Epub 2015 Jun 15. No abstract available.

PMID:
26078469
20.

Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting.

Luo FR, Ding J, Chen HX, Liu H, Fung MC, Koehler M, Armand JP, Jiang L, Xu X, Zhang G, Xu L, Qian P, Yan L.

Chin J Cancer. 2014 Dec;33(12):620-4. doi: 10.5732/cjc.014.10246. Epub 2014 Nov 21.

21.

A catalyst for change: the European cancer Patient's Bill of Rights.

Lawler M, Le Chevalier T, Murphy MJ Jr, Banks I, Conte P, De Lorenzo F, Meunier F, Pinedo HM, Selby P, Armand JP, Barbacid M, Barzach M, Bergh J, Bode G, Cameron DA, de Braud F, de Gramont A, Diehl V, Diler S, Erdem S, Fitzpatrick JM, Geissler J, Hollywood D, Højgaard L, Horgan D, Jassem J, Johnson PW, Kapitein P, Kelly J, Kloezen S, La Vecchia C, Löwenberg B, Oliver K, Sullivan R, Tabernero J, Van de Velde CJ, Wilking N, Wilson R, Zielinski C, Zur Hausen H, Johnston PG.

Oncologist. 2014 Mar;19(3):217-24. doi: 10.1634/theoncologist.2013-0452. Epub 2014 Feb 3. No abstract available.

22.

Task-specific performance effects with different numeric keypad layouts.

Armand JT, Redick TS, Poulsen JR.

Appl Ergon. 2014 Jul;45(4):917-22. doi: 10.1016/j.apergo.2013.11.008. Epub 2013 Dec 4.

PMID:
24315462
23.

Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples.

Lazar V, Lassau N, Meurice G, Loriot Y, Peña C, Massard C, Robert C, Robert T, Le Berre MA, de Baere T, Dessen P, Soria JC, Armand JP.

Invest New Drugs. 2014 Apr;32(2):312-22. doi: 10.1007/s10637-013-9993-0. Epub 2013 Aug 27.

PMID:
23979492
24.

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.

Soria JC, Baselga J, Hanna N, Laurie SA, Bahleda R, Felip E, Calvo E, Armand JP, Shepherd FA, Harbison CT, Berman D, Park JS, Zhang S, Vakkalagadda B, Kurland JF, Pathak AK, Herbst RS.

Eur J Cancer. 2013 May;49(8):1815-24. doi: 10.1016/j.ejca.2013.02.012. Epub 2013 Mar 13.

PMID:
23490650
25.

Early evaluation of targeted drugs using dynamic contrast-enhanced ultrasonography for personalized medicine.

Lassau N, Cosgrove D, Armand JP.

Future Oncol. 2012 Oct;8(10):1215-8. doi: 10.2217/fon.12.114. No abstract available.

PMID:
23130922
26.

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.

Massard C, Margetts J, Amellal N, Drew Y, Bahleda R, Stephens P, Armand JP, Calvert H, Soria JC, Coronado C, Kahatt C, Alfaro V, Siguero M, Fernández-Teruel C, Plummer R.

Invest New Drugs. 2013 Jun;31(3):623-30. doi: 10.1007/s10637-012-9843-5. Epub 2012 Jun 12. Erratum in: Invest New Drugs. 2013 Jun;31(3):799. Stevens, Peter [corrected to Stephens, Peter].

PMID:
22688291
27.

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors.

Massard C, Salazar R, Armand JP, Majem M, Deutsch E, García M, Oaknin A, Fernández-García EM, Soto A, Soria JC.

Invest New Drugs. 2012 Dec;30(6):2318-26. doi: 10.1007/s10637-011-9772-8. Epub 2012 Jan 4.

PMID:
22215532
28.

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.

Gomez-Roca CA, Lacroix L, Massard C, De Baere T, Deschamps F, Pramod R, Bahleda R, Deutsch E, Bourgier C, Angevin E, Lazar V, Ribrag V, Koscielny S, Chami L, Lassau N, Dromain C, Robert C, Routier E, Armand JP, Soria JC.

Ann Oncol. 2012 May;23(5):1301-6. doi: 10.1093/annonc/mdr383. Epub 2011 Sep 14.

PMID:
21917737
29.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Soria JC, Cortes J, Massard C, Armand JP, De Andreis D, Ropert S, Lopez E, Catteau A, James J, Marier JF, Beliveau M, Martell RE, Baselga J.

Ann Oncol. 2012 Feb;23(2):463-71. doi: 10.1093/annonc/mdr137. Epub 2011 May 16.

PMID:
21576284
30.

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.

Massard C, Soria JC, Anthoney DA, Proctor A, Scaburri A, Pacciarini MA, Laffranchi B, Pellizzoni C, Kroemer G, Armand JP, Balheda R, Twelves CJ.

Cell Cycle. 2011 Mar 15;10(6):963-70. Epub 2011 Mar 15.

PMID:
21368575
31.

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.

Brendel E, Ludwig M, Lathia C, Robert C, Ropert S, Soria JC, Armand JP.

Cancer Chemother Pharmacol. 2011 Jul;68(1):53-61. doi: 10.1007/s00280-010-1423-9. Epub 2010 Sep 7.

32.

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.

Boven E, Massard C, Armand JP, Tillier C, Hartog V, Brega NM, Countouriotis AM, Ruiz-Garcia A, Soria JC.

Br J Cancer. 2010 Sep 28;103(7):993-1000. doi: 10.1038/sj.bjc.6605852. Epub 2010 Aug 17.

33.

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

Soria JC, Massard C, Magné N, Bader T, Mansfield CD, Blay JY, Bui BN, Moussy A, Hermine O, Armand JP.

Eur J Cancer. 2009 Sep;45(13):2333-41. doi: 10.1016/j.ejca.2009.05.010. Epub 2009 Jun 21.

PMID:
19541476
34.

Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer.

Massabeau C, Rouquette I, Lauwers-Cances V, Mazières J, Bachaud JM, Armand JP, Delisle MB, Favre G, Toulas C, Cohen-Jonathan-Moyal E.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):696-702. doi: 10.1016/j.ijrobp.2008.11.050. Epub 2009 Apr 20.

PMID:
19386436
35.

Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.

Domont J, Massard C, Lassau N, Armand JP, Le Cesne A, Soria JC.

Invest New Drugs. 2010 Apr;28(2):199-202. doi: 10.1007/s10637-009-9249-1. Epub 2009 Apr 8. No abstract available.

PMID:
19352594
36.

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T.

J Clin Oncol. 2009 Mar 10;27(8):1268-74. doi: 10.1200/JCO.2008.17.5984. Epub 2009 Feb 9.

37.

Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors.

Armand JP, Ribrag V, Harrousseau JL, Abrey L.

Ther Clin Risk Manag. 2007 Jun;3(2):213-24.

38.

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.

Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, Massard C, Armand JP, Soria JC.

Nat Clin Pract Oncol. 2008 May;5(5):268-78. doi: 10.1038/ncponc1087. Epub 2008 Mar 18. Review. Erratum in: Nat Clin Pract Oncol. 2009 Mar;6(3):180. Penault-Lorca, Frédérique [corrected to Penault-Llorca, Frédérique].

PMID:
18349858
39.

Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.

Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, Magné N, Pignon JP, Vassal G, Armand JP, Soria JC.

Ann Oncol. 2008 Apr;19(4):787-92. Epub 2007 Nov 27. Review.

PMID:
18042834
40.

[Oral drugs inhibiting the VEGF pathway].

Ropert S, Mir O, Armand JP.

Bull Cancer. 2007 Jul;94 Spec No:S180-90. Review. French.

PMID:
17846003
41.

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.

de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, Pierron G, Pinna G, Araujo N, Harel-Belan A, Armand JP, Wong TW, Soria JC, Kroemer G.

Cancer Res. 2007 Jul 1;67(13):6253-62.

42.

QTc monitoring during a phase I study: experience with SR271425.

Soria JC, Dieras V, Girre V, Yovine A, Mialaret K, Armand JP.

Am J Clin Oncol. 2007 Apr;30(2):106-12.

PMID:
17414458
43.

The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.

Armand JP, Burnett AK, Drach J, Harousseau JL, Löwenberg B, San Miguel J.

Oncologist. 2007 Mar;12(3):281-90. Review.

44.

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.

Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C.

Clin Cancer Res. 2007 Mar 15;13(6):1801-9.

45.

Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene.

Queille S, Luron L, Spatz A, Avril MF, Ribrag V, Duvillard P, Hiesse C, Sarasin A, Armand JP, Daya-Grosjean L.

Carcinogenesis. 2007 Mar;28(3):724-31. Epub 2006 Oct 25.

PMID:
17065198
46.

Targeting angiogenesis with oral agents.

Besse B, Armand JP, Soria JC.

Ann Oncol. 2006 Sep;17 Suppl 10:x71-5. Review. No abstract available.

PMID:
17018755
47.

Nasopharyngeal carcinoma and therapeutic management: the place of chemotherapy.

Guigay J, Temam S, Bourhis J, Pignon JP, Armand JP.

Ann Oncol. 2006 Sep;17 Suppl 10:x304-7. Review. No abstract available.

PMID:
17018743
48.

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies.

Ghesquières H, Faivre S, Djafari L, Pautier P, Lhommé C, Lozahic S, Djazouli K, Armand JP, Raymond E.

Invest New Drugs. 2006 Sep;24(5):413-21.

PMID:
16763786
49.

[Targeting angiogenesis in oncology].

Fayette J, Soria JC, Armand JP.

Pathol Biol (Paris). 2006 May;54(4):199-205. Epub 2005 Jan 20. Review. French.

PMID:
16753494
50.

Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.

Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP Jr.

Cancer J. 2006 Jan-Feb;12(1):47-53.

PMID:
16613662

Supplemental Content

Loading ...
Support Center